title: Which thrombolytic agent should one choose?
authors.affiliation: Department of Cardiology, Cleveland Clinic Foundation, OH 44195.
authors.forename: E J
authors.initials: EJ
authors.lastname: Topol
mesh_terms: D016255:Anistreplase / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005337:Fibrin / Q000187:drug effects; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D013300:Streptokinase / Q000494:pharmacology / Q000627:therapeutic use*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000494:pharmacology / Q000627:therapeutic use*; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D016255:Anistreplase; D005337:Fibrin; D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator